Bristol Myers Squibb Company - Bathi saben saham sajrone 12 wulan pungkasan BMY

Logo perusahaan publik Bristol Myers Squibb Company (BMY)

Bristol-Myers Squibb (BMY) focuses on the global targeted therapy market, refreshing its portfolio through the acquisition of startups. Its status as a recognized innovator in immunology strengthens physician confidence. A year-over-year EPS (TTM) comparison confirms the business's resilience, where the value of 52.80 characterizes this level. However, the expiration of patents on key drugs is temporarily reducing the holding's overall margins.

BMY Bristol Myers Squibb Company: Bathi saben saham sajrone rolas wulan pungkasan ing interval 11.02.2024 - 18.11.2026

Bristol-Myers Squibb - rincian analitis lan metrik utama (BMY)

- rega saham lan prakiraan rega para ahli:
- rincian nilai pasar emiten:
Analisis wiwitan perusahaan:Bristol Myers Squibb BMY
Produk mawa merek Bristol-Myers Squibb Co.

Bristol-Myers Squibb (BMY) resilience to market volatility is driven by stable demand for patented oncology and cardiovascular therapies. The profitability dynamics of this business are reflected in the 12-month YoY EPS trend, which smooths quarterly gaps via a rolling annual window. This metric measures the actual growth in net income per share while neutralizing reporting seasonality. Investors should note that even with a positive trend, high borrowing costs may exert pressure on capital margins.